Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC) and also act as a treatment strategy to stop the spread of the disease.
Advanced Cell Technology announced the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
Watson Pharmaceuticals Inc. said on June 17 a federal court denied requests for a preliminary injunction and temporary restraining order to prevent it from launching a generic version of the contraceptive Seasonique.
NIH scientists deciphered a key biochemical step that the bacteria that cause Legionnaire’s disease use to reproduce.
Syngene has unveiled its GeneGnome5, a dedicated chemiluminescent imaging system designed to make precise imaging of chemiluminescent Western blots a simple, one click task.
AMSBIO announces ec23, a stable synthetic retinoid that has been proven in independent testing to potently induce and reliably control stem cell differentiation.
QIAGEN N.V. has entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and offered to fully acquire the company, which specializes in molecular profiling and personalized healthcare diagnostics.
Stem cell technologies have been proposed for cell-based diagnostics and regenerative medicine therapies. However, being able to make stem cells efficiently develop into a desired cell type limits the clinical potential of these technologies.
Reata Pharmaceuticals, Inc. and Abbott announced the initiation of a Phase 3 trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
The Supreme Court will let two West Virginia residents revive a lawsuit against Bayer AG over its anti-cholesterol drug Baycol, which was withdrawn from the market in 2001 after reports of a severe and sometimes fatal muscle disorder.
Super bugs, which can cause wide-spread disease and may be resistant to most, if not all, conventional antibiotics, still have their weaknesses.
A potential treatment for advanced lung cancer from Pfizer Inc. has about an 80%chance of receiving Food and Drug Administration approval this year, according to a Credit Suisse analyst.
Cubist Pharmaceuticals Inc. said it will move an experimental antibiotic into late-stage clinical testing as a treatment for complex infections of the urinary tract and abdomen.
OpenClinica 3.1 helps the productivity of clinical trials through open source electronic data capture software.
IO Informatics’ Knowledge Explorer Personal Edition provides semantic data integration to help users meet data integration needs, improve data interoperability, and remove barriers to innovation by providing free access to software that makes previously complex data integration tasks easy.